TKIs Appear Safe in Patients With Chronic Myeloid Leukemia, CKD
the ONA take:
Tyrosine kinase inhibitors (TKIs) seem safe in patients with chronic myeloid leukemia (CML) in chronic-phase and chronic kidney disease, a recent study published online ahead of print in the journal Cancer has shown.
For the study, researchers investigated the incidence of acute injury and chronic kidney disease in 468 patients with newly diagnosed chronic-phase CML who were treated with imatinib, dasatinib, or nilotinib.
Results showed that 4% of patients experienced TKI-associated acute kidney injury. Researchers found that imatinib was associated with an increased incidence of acute kidney injury compared with dasatinib and nilotinib.
The study also demonstrated that 14% of patients developed chronic kidney disease while receiving TKI treatment. Of those, 84% were receiving imatinib. However, in patients with a history of chronic kidney disease, imatinib did not cause a significant decline in glomerular filtration rate.
"The administration of TKIs may be safe in the setting of CKD in CP CML patients, but close monitoring is still warranted," Musa Yilmaz, M.D., from the Baylor College of Medicine in Houston, TX, and colleagues wrote.
Tyrosine kinase inhibitors seem safe in patients with chronic myeloid leukemia in chronic-phase and chronic kidney disease.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|